

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001801917
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Roivant Sciences Ltd.
SEC File Number 001-40782
Address of Issuer CLARENDON HOUSE, 2 CHURCH STREET
HAMILTON HM11
BERMUDA
HM11
Phone 441-295-5950
Name of Person for Whose Account the Securities are To Be Sold Venker Eric

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza - Floor 5 New York NY 10111	117372	1397752.56	766811433	07/31/2023	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from	Is this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	---------------------	---------	------------	----------------------	-----------------	---------------------

	Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Common	Options Exercise - 07/31/2023 Grant Date 4/20/2022	Roivant Sciences Ltd.	<input type="checkbox"/>	117372	07/31/2023 Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/01/2023	61155	525251.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/02/2023	109074	897477.32
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/03/2023	118760	997196.40
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/04/2023	88838	737504.16
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/08/2023	61206	546237.33
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/09/2023	238724	2204059.84
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/23/2023	15671	150128.18
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	05/23/2023	415	4087.75
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/07/2023	201	1979.85
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/09/2023	299384	2967299.96
Eric Venker c/o Roivant Sciences Ltd. 7th Floor	Common	06/22/2023	15882	158978.82

50 Broadway London X0 SW1H 0DB Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common	07/20/2023 159387	1802034.65
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	Common	07/21/2023 181998	2025358.44
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common	07/21/2023 28937	322068.81
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common shares	07/24/2023 16297	179104.03
Eric Venker c/o Roivant Sciences Ltd. 7th Floo 50 Broadway London X0 SW1H 0DB	Common Shares	07/24/2023 33081	361645.23
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	Common shares	07/25/2023 28344	307869.19
Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB	common shares	07/26/2023 28344	307869.19
Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB	common shares	07/27/2023 23622	259448.15

144: Remarks and Signature

Remarks	The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/25/2023.
Date of Notice	07/31/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/25/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature	Audrey Skillern as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker
-----------	---

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)